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Abstract: Behavioral and psychological symptoms are almost universal in elderly patients with
dementia. Antipsychotic drugs can be used but only in specific contexts as they can generate severe
adverse effects. The main aim of this research was to evaluate the use of antipsychotic drugs in
patients with accompanying treatment for dementia in actual clinical practice in primary health
care. We further sought to analyze risk variables and factors associated and to acknowledge how
sociodemographic and clinical factors weighed on adverse effects’ occurrence. A multicentric cross-
sectional descriptive study was performed in three provinces of Spain. Stratified random sampling
was performed to select 332 patients. Clinical data from their digital medical records were collected
by their family doctors. The Global risk defined if the patients were subjected to risk. Univariate,
bivariate, and multivariate analyses were performed. The most used antipsychotics were quetiapine
(65.5%), haloperidol (21.75%), and risperidone (15.8%); 93.8% of patients showed risk, and 81.1% of
doses and 75.5% of treatment durations were inappropriate. These two last factors increased the
global risk 23 and 20 times, respectively. Conclusions: In actual clinical practice conditions, a high
use of antipsychotic drugs was found in patients with dementia. Most patients had inappropriate
doses and treatment duration, factors that increased the risk of adverse effects considerably.
Keywords: antipsychotic; dementia; elderly; primary health care; actual clinical practice
1. Introduction
Dementia is one of the major causes of disability and dependence among older peo-
ple. Ten million cases occur each year around the globe, age being the main risk for its
development. Due to increasing lifespan and the ageing of the population in the developed
and developing countries, dementia represents a fundamental challenge for public health
systems. It is expected that the number of people with dementia will be 82 million in 2030,
and 152 million in 2050 [1,2].
Behavioral and psychological symptoms of dementia consist of two groups of symp-
toms: Behavioral symptoms are identified by observation of the patients, and they include
aggressiveness, screaming, or agitation, among others. Psychological symptoms can be
identified through an interview with the patients or their caregivers, and they include anxi-
ety or hallucinations, among others. In addition to cognitive impairment, symptoms such
as agitation, aggressiveness, or hallucinations are almost universal in these patients [2,3],
and they can be distressing for patients and for their caregivers. Clinical practice guidelines
based on evidence suggest use of antipsychotics if the patients are seriously affected or if
they are at risk of harming themselves or other people. These guidelines recommend using
the lowest doses of drugs over the shortest time possible, given their adverse effects that in-
clude risk of falls, stroke, and death [4–7]. Therefore, the use of antipsychotics in dementia
is controversial and should be considered only in patients with severe symptoms and when
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other measures have failed. These drugs should not be indicated in patients with mild or
moderate symptoms, and nonpharmacological treatment should be considered [4–6].
If agitation or aggressiveness are persistent, recurrent, or severe, or if they generate
distress among patients or their caregivers [5,7–9], the first treatment option is risperi-
done, the only atypical antipsychotic authorized in some countries [4,10]. There is also
effectiveness evidence described for olanzapine and aripiprazole, but these drugs should
be considered only as an alternative in special situations [6,7,11–13]. Quetiapine could
be considered in dementia with Lewy bodies and Parkinsons, but only if there are no
other options available [6,7]. First generation antipsychotics, such as haloperidol, can also
be useful for acute treatment [4,6,7]. They can be effective as atypical antipsychotics [5],
but actual evidence does also show that they are less safe [7,14]. Using an inappropriate
antipsychotic involves a risk for the patient. An antipsychotic is considered inappropriate
if it is not authorized for short-term use in persistent aggressiveness that can appear in
patients with moderate to severe Alzheimer-like dementia, and who do not respond to non-
pharmacological treatment. The use of antipsychotic drugs can increase the risk of adverse
effects such as prolongation of the QT-interval, generated by the drugs used for dementia
treatment [10,15], extrapyramidal adverse effects, or even death [10,16–20]. Thus, before
prescribing antipsychotic drugs it is important to rule out other comorbidities [4,5,7,9].
Some research shows that behavioral disorders of dementia are intermittent and rarely
persist more than three months [21]. Hence, the effectiveness of treatments should be
evaluated within the first 2–4 weeks, and every 3–4 months, using the same scale and
criteria used in previous evaluations [4–7,9–22]. Lack of clinical response or adverse
effects occurrence are criteria to stop treatments with antipsychotic drugs [4,23,24]. These
treatments should not become chronic if there is not a medical indication based on evidence.
For example, taking advantage of the sedative properties of quetiapine to treat symptoms
such as insomnia is not an indication to extend a treatment [25].
Over the past years, increased attention has been given to the use of these treatments
in actual clinical practice and their effectiveness in different conditions [21,26–28]. Never-
theless, in numerous cases, the clinical trials performed studied patients that did not reflect
actual clinical practice [27,28]. Moreover, as far as we know, there is no evidence from actual
clinical practice in primary health care about health outcomes in patients with dementia
treated with antipsychotic drugs, the adequacy of these treatments, or the evaluation of
their duration and efficacy. Therefore, our research focused on the use of these drugs in
actual clinical practice, as this should enable design of intervention programs to improve
the adequacy of the use of antipsychotics in patients with dementia, ensuring their safety.
Therefore, the main aim of this research was to review the use of antipsychotic drugs
in patients with accompanying treatment for dementia, in actual clinical practice in primary
health care. We further sought to analyze risk variables and factors that are associated with
these patients, such as the risk associated with inappropriate use of drugs or inappropriate
treatment duration, and to acknowledge how sociodemographic and clinical factors weigh
on adverse effects’ occurrence.
2. Results
2.1. Use of Antipsychotic Drugs in Patients with Dementia in Actual Clinical Practice in Primary
Health Care
The analysis of the patients with concomitant treatment of anti-dementia and antipsy-
chotic drugs showed that 75.2% of these treatments were initiated in primary health care.
No statistically significant differences were found among these treatments in the three
provinces. The usage profile of the drugs is shown in Table 1.
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No 98 (95.1%) 126 (100%) 93 (100%)
0.003
Yes 5 (4.9%) 0 (0.0%) 0 (0.0%)
Haloperidol
No 90 (87.4%) 90 (71.4%) 72 (77.4%)
0.014
Yes 13 (12.6%) 36 (28.6%) 21 (22.6%)
Aripiprazole
No 102 (99.1%) 125 (99.2%) 93 (100%)
0.49
Yes 1 (0.9%) 1 (0.8%) 0 (0.0%)
Quetiapine
No 30 (29.1%) 48 (38.1%) 33 (35.5%)
0.35
Yes 73 (70.9%) 78 (61.9%) 60 (64.5%)
Sulpiride
No 91 (88.3%) 116 (92.1%) 91 (97.8%)
0.02
Yes 12 (11.7%) 10 (7.9%) 2 (2.2%)
Risperidone
No 89 (86.4%) 109 (86.5%) 73 (78.5%)
0.20
Yes 14 (13.6%) 17 (13.5%) 20 (21.5%)
The most widely used antipsychotic drugs in our sample were the following: 65.5% of
the patients used quetiapine (n = 211); 21.7% of the patients used haloperidol (n = 70); and
15.8% of the patients used risperidone (n = 51). The least used drug was aripriazol, found
in 0.6% of the patients (n = 2). According to their use among the three provinces analyzed,
statistically significant differences were found for olanzapine (p < 0.003), haloperidol
(p = 0.01), and sulpiride (p = 0.02). When analyzing the use of antipsychotic drugs according
to the residency area of the patients, statistically significant differences were found for
quetiapine (p = 0.01), twice as likely to be used in urban areas (OR 1.81; CI 1.09–2.99) than
in rural areas. No statistically significant differences were found in the use of antipsychotic
drugs according to gender.
2.2. Analysis of Global Risk Variables and Specific Sociodemographic Factors to Assess the Risk of
the Patients
The patients’ risk was assessed according to the antipsychotic drugs used, the gender,
and the health district, and the results are shown in Table 2.
As these patients were older than 65 and most of them were polymedicated, the
existence of other inappropriate drugs was also analyzed, according to Stop/Start criteria.
Inappropriate drugs were found in 91.3% of these patients (Table 2), and no statistically
significant differences were found according to the health districts, gender, or setting.
When analyzing the Global Risk related to the treatment, 93.8% of patients showed some
kind of risk, and no statistically significant differences were found according to the health
districts, gender, or setting. When analyzing the five specific levels of risk, 4.7% of patients
were categorized as Risk 4; 56.8% as Risk 3; 32.3% as Risk 2; 5.6% as Risk 1; and 0.6% as
Risk 0. No statistically significant differences were found according to the health districts,
gender, or setting.
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2.3. Multivariate Analysis
After applying the Hosmer-Lemeshow analysis (Chi-squared = 0.06; Sig 0.96) and the
Nagelkerke’s R Square (0.66) for goodness of fit, the variables included in the model were
the following: inappropriate doses, which increased the global risk 23 times; and inappro-
priate duration time of the treatment, which increased the global risk 20 times (Table 3).
Thus, the logistic regression model included the inappropriate doses and inappropriate
duration time of the treatment variables and it excluded the following variables: gender,
age, use of olanzapine, quetiapine, haloperidol, or risperidone as risk factors for stroke
or death.
Table 3. Multivariate Analysis.
Exp (B)
95% C.I. for Exp (B)
p
Lower Superior
Inappropriate doses 215.51 23.01 2017.70 0.001
Inappropriate treatment
duration 208.41 20.84 2084.23 0.001
3. Discussion
The main aim of this research was to evaluate the use of antipsychotic drugs in patients
with accompanying treatment for dementia in actual clinical practice in primary health
care. We further sought to analyze risk variables and factors that were associated with
these patients and to acknowledge how sociodemographic and clinical factors weighed on
adverse effects occurrence.
One interesting finding was that none of the health records of the patients analyzed
included a clinical evaluation of the presence of behavioral symptoms, such as the Cum-
ming’s Neuropsychiatric Inventory, before initiating antipsychotic treatment. As numerous
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authors state, this evaluation should be performed in every patient with dementia, previous
to treatment [4,5,7,9].
Regarding the use of antipsychotic drugs in these patients, quetiapine was used in
65.5% of the patients, haloperidol in 21.7%, risperidone in 15.8%, and aripiprazole in
0.65%. As only risperidone has this indication of use in its data sheet [10], it should be
the first-choice treatment in patients with dementia and severe behavioral symptoms [4,7],
and for no more than 4–6 weeks [4,6,10,22]. Haloperidol is indicated for the treatment of
persistent aggressiveness and psychotic symptoms in patients with dementia [10] but, due
to its safety profile, it should be used only as an emergency drug and for a short period of
time [4–6]. Quetiapine could be an alternative for the treatment of dementia with Lewy
bodies, if there are no other options available [6,7]. There is also evidence of the efficacy
of olanzapine and aripiprazole, but they should be used as an alternative [6,7] when first
choice treatments do fail [11].
Some research shows that the risks of using antipsychotic drugs in patients with
dementia are greater than the potential benefits [22]. Therefore, they should be used only
when nonpharmacologic measures have failed or in emergency situations and for a short
period of time. A behavioral symptoms evaluation should be performed previous to the
treatment with antipsychotic drugs. In addition, the doses of the antipsychotic drugs, when
treating symptoms such as agitation, must be lower than the dosage used as antipsychotic
drugs, [4–6,9]. Contrary to this, in our research, treatment duration with antipsychotic
drugs was longer than one year in 56.8% of the patients, and low doses of these drugs,
which are recommended [4–7], were used in only 18.9% of the patients.
The proportion of adverse effects appearance in these patients is around 25% [18,24,29].
The most common are drowsiness, migraines, appetite changes, and weight gain or anti-
cholinergic symptoms such as slow march, tremors, hypersalivation, and loosening of facial
expressions. Among severe adverse effects, we can find stroke and even death [19,20,24].
About 12 in 1000 patients, with dementia and antipsychotic drug treatment, will suffer a
stroke, and about 11 in 1000 of them will die [4,5].
These figures differ from the findings of our research, where only 1.2% of the patients
had adverse effects reflected in their medical records. A plausible explanation for this is that,
as the mean age of our patients was 82.41 years, and 74.8% were polymedicated, it would
have been difficult to differentiate between the presence of adverse effects related to the
use of antipsychotic drugs, and the presence of symptoms related to their age and clinical
situation. Thus, the adverse effects of the antipsychotic drugs may be underestimated
in the medical records of the patients of our research. In fact, 10.9% of patients in our
research had a stroke and 2.2% died; however, other adverse effects such as drowsiness,
agitation, aggressiveness, or extrapiramidal disorders, were under 1%. Therefore, we
cannot conclude whether the adverse effects found in the medical records analyzed were
due to the use of antipsychotic drugs or to other clinical or pharmacological factors.
The logistic regression model allowed us to conclude that gender, age, use of olanzap-
ine, quetiapine, haloperidol, or risperidone did not influence the risk of stroke or death,
which are the major adverse effects described in the literature [4–6,14,18,29,30]. The only
two variables that remained included in the model were inappropriate doses, which in-
creased the global risk 23 times, and inappropriate treatment duration, which increased the
global risk 20 times. A viable explanation for this is that the number of patients analyzed,
despite being 322, could be low to properly detect rare events such as stroke or death. We
have not found other research with a similar methodology, performed in actual clinical
practice, in primary health care, so we cannot compare these last findings.
This research had some limitations and strengths. The main limitation was the lack
of records in some of the clinical medical records analyzed. Due to this, we decided to
increase by 10% the number of patients required. Although the population studied was
large, this research was a cross-sectional prevalence survey, so the drug types used and
prevalence of use may have reflected local factors. Moreover, interpreting cross-sectional
associations is difficult. Another limitation is that the research was based on primary health
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care records from public health, so it did not consider patients that had been treated in
hospitals or at private facilities. Therefore, these aspects could limit the external validity
of the results. Antipsychotic drugs have limited evidence for considering them for the
treatment of behavioral and psychological symptoms of dementia. They are also associated
with an increase in the risk for those patients. As a consequence, only a few of these
antipsychotic drugs, previously approved by national or regional regulatory agencies,
can be used for the treatment of severe behavioral disorders. This makes it difficult to
find association factors for antipsychotic medications, and is another potential limitation
that could be considered. As they were not part of the main aims of this research, other
factors, such as disease severity, comorbidities, functional ability, life style habits, or family
supporting, were not analyzed. Hence, these factors could be considered for future research.
One strength of our research was the number of participants, above the required number.
Another important aspect is that our research was performed in actual clinical practice in
primary care, where most of these patients receive treatment, so it can be useful for the
actual clinical practice of numerous professionals.
4. Methods
4.1. Study Population
A multicentric cross-sectional descriptive study was performed from March 2019
to February 2020 in three health districts of three provinces of Spain (Almería, Granada,
and Málaga), which covered a total population of 1,741,888 people. The targeted study
population was people with dementia, with an age of over 65, and concomitant treatment
of drugs for dementia and antipsychotics, prescribed by primary health care doctors.
4.2. Sampling Procedure
The total number of patients with concomitant treatment of drugs for dementia and
antipsychotics was 2743 patients, distributed as follows: 896 in Almeria, 1056 in Granada,
and 774 in Málaga. The software Ene 3.0 (Universidad Autónoma de Barcelona, Barcelona,
Spain) was used to calculate the required sample size. Assuming that the adverse effects
ratio in these patients was about 25% [29], it was necessary to include at least 290 patients
in the research. Considering a maximum attrition rate of 10%, the total number of patients
to include was 332. They were stratified according to the setting where they lived (urban
or rural). The percentages of patients who lived in urban areas (56.6% in Almería, 84.8%
in Granada, and 73.6% in Málaga) was used to obtain the required number of patients
for each setting in each health district. Stratified random sampling was performed for
each health district and setting with proportional allocation, using EPIDAT 4.2 software
(Consellería de Sanidade, Xunta de Galicia, Spain). The results are shown in Table 4.
Table 4. Number of patients required for each health district.
Setting
Province Rural Urban Total
Almería 46 35 81
Granada 143 26 169
Málaga 53 19 72
4.3. Data Collection
The software MicroStrategy (MicroStrategy Incorporated, McLean, VA, USA) was
used to exploit pharmacy data available in the three provinces, enabling the filtering of
patients by age, gender, and period of study. The drugs used were classified in the database
according to the Anatomical Therapeutic Chemical Classification (ATC). Drugs for demen-
tia treatment were included in therapeutic group N06D, which included two subgroups,
06DA for cholinesterase inhibitor drugs and N06DX for other drugs for dementia. Antipsy-
chotic drugs were included in therapeutic group N05A. The researchers of each health
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district trained the family doctors of the selected patients to collect clinical data from their
digital medical records in one single session. No personal data were collected.
4.4. Data Analysis
For descriptive analysis of the collected variables, central tendency and dispersion
measures were used for quantitative variables absolute frequencies were used for qualita-
tive variables, and 95% confidence intervals (CI) were calculated for means and proportions.
The goodness of fit to normality for the variables was calculated using the Kolmogorow–
Smirnov test.
For risk assessment, the following criteria were applied: use of an inappropriate
antipsychotic (aripiprazole, sulpiride, levomepromazine, chlorpromazine, and paliperi-
done); use of inappropriate doses (normal or high); inappropriate treatment duration (more
than four months); use of other inappropriate drugs, according to Stop/ Start Criteria [6].
According to these factors, the risk for each patient was ranked in five levels: Risk 4—the
patient met four criteria; Risk 3—the patient met three criteria; Risk 2—tThe patient met
two criteria; Risk 1—the patient met one criteria; Risk 0—the patient met no criteria. The
Global risk defined if the patients were subjected to risk. Global risk was considered low
for those patients with a risk rank between 0 and 1, and it was considered high for those
patients with a risk rank between 2 and 4.
To perform bivariate analysis, the parametric Student’s t-test was used for indepen-
dent samples and the nonparametric Mann–Whitney test was used to compare the main
quantitative variables between the patients who showed adverse effects and those who did
not. For qualitative variables, the Pearson Chi-squared test and Fisher’s exact test were
used. The Kaplan–Meier method was used to find the survival table and curve.
To perform multivariate analysis, the association of the adverse effects of stroke and
death with the independent variables was identified using odds ratio calculation. To
define to what extent the associations found were explained by the effect of the rest of
the variables collected in the research, a multivariate predictive regression model was
used, and confidence intervals at 95% were calculated. The dependent variable was the
global risk, and the independent variables were the following: province, setting, gender,
age, use of inappropriate psychiatric drugs, use of inappropriate doses, inappropriate
treatment duration, use of contraindicated drugs, and if patients were institutionalized.
For binary logistic regression analysis, the dependent variables were stroke and death,
and the independent variables were the following: gender, age, use of olanzapine, use of
quetiapine, use of haloperidol, use of risperidone, inappropriate doses, and inappropriate
treatment duration. Statistical analyses were performed using STATA version 12 (StataCorp
LLC, College Station, TX, USA).
Ethical Aspects and Review Board Approval: This was a cross-sectional study based
on clinical data previously existing in medical records. The data was collected by the family
doctors of randomly selected patients, and no personal information was collected, so data
was anonymous and no informed consent was required. All collected data was processed
according to Regulation (EU) No 679/2016 of the European Parliament; to General Registry
for the Protection of Personal Data under the Spanish Data Protection Agency Law of
27 April 2016; and to Spanish Organic Law 3/2018, of December 5, about protection of
personal data and digital rights warranty. All the procedures described in this study were
approved by the Research and Ethics Committee of the Province or Almeria (Spain), with
approval number 42/2019.
5. Conclusions
This research detected a high level of use of antipsychotic drugs in patients with
dementia. Most of them were women who lived in an urban setting. The most used drugs
were quetiapine, haloperidol, and risperidone, with no differences among provinces, or re-
lated to gender or setting, except for quetiapine, which was used twice as much in patients
from rural setting. As a consequence of using antipsychotic drugs with other concomitant
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treatments, 93.8% of the patients had an increased level of risk, but no differences were
found according to the province, gender, or setting. These drugs are being using without a
behavioral symptoms evaluation in the medical records or the use of other nonpharma-
cological measures, previous to the treatment with antipsychotic drugs. Inappropriately
high doses for the treatment of behavioral symptoms were found in 81.1% of the patients,
and the duration treatment was inappropriate in 75.5% of them. No evaluation records at
2–4 weeks were found. These two last aspects (inappropriate doses and inappropriate treat-
ment duration) increased the global risk 23 and 20 times, respectively, with no differences
according to province, gender, or setting.
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